Ten years of progress in melanoma

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 10, Issue 8, 2012, Pages 932-935

  Thompson, John A ^a,b,c,d,e  

^a Phase I Clinical Trials Program   (United States)

^b SEATTLE CANCER CARE ALLIANCE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e American Association for Cancer Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBINTERFERON ALPHA2B; DACARBAZINE; IPILIMUMAB; PEGINTERFERON;

CANCER INCIDENCE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; FOOD AND DRUG ADMINISTRATION; HUMAN; LYMPHADENECTOMY; MELANOMA; MULTIPLE CYCLE TREATMENT; NOTE; SENTINEL LYMPH NODE BIOPSY; SIGNAL TRANSDUCTION;

EID: 84865315390     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2012.0096     Document Type: Note

References (15)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics 2002. CA Cancer J Clin 2002;52:23-47.
2. Siegel R, Naishadhum D, Jemal A. Cancer statistics 2012. CA Cancer J Clin 2012;62:1-69.
3. International Agency for Research on Cancer Working Group on Artificial Ultraviolet (UV) Light and Skin Cancer. The association of use of sunbeds with cutaneous malignant melanoma and other skin cancers: a systematic review. Int J Cancer 2007;120:1116-1122.
4. Swerdlow A, Weinstock M. Do tanning lamps cause melanoma? An epidemiologic assessment. J Am Acad Dermatol 1998;38:89-98.
5. Balch C, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199-6206.
6. Coit D, Andtbacka R, Anker CJ, et al. NCCN Clinical Practice Guidelines in Oncology: Melanoma. Version 3, 2012. Available at NCCN.org. Accessed July 2, 2012.
7. Kirkwood JM, Manola J, Ibrahim J, et al. A pooled analysis of Eastern Cooperative Oncology Group and Intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004;10:1670-1677.
8. Eggermont A, Suciu S, Santinami M, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008;372:117-126.
9. Morton D, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy of nodal observation in melanoma. N Engl J Med 2006;355:1307-1317.
10. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival wth ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-723.
11. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-2526.
12. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-2516.
13. Hunder NN, Wallen H, Cao J, et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 2008;358:2698-2703.
14. Restifo N, Dudley M, Rosenberg S. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012;12:269-281.
15. Bhatia S, Thompson J. Systemic therapy for metastatic melanoma in 2012: dawn of a new era. J Natl Compr Canc Netw 2012;10:403-412.